Evidence map›Paper›PMID 37890671›Full record

ArticleThe American journal of clinical nutrition2024

Placental ferroportin protein abundance is associated with neonatal erythropoietic activity and iron status in newborns at high risk for iron deficiency and anemia.

Alexa Barad, Ronnie Guillet, Eva K Pressman, Philip J Katzman, Tomas Ganz, Elizabeta Nemeth, Kimberly O O'Brien

2 registry-linked trialsOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of clinical nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01019902 completednot on this map

Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn

TypeobservationalSponsorCornell UniversityRan2008 to 2013Enrolled144ConditionsAnemia
NCT01582802 unknown statusnot on this map

Determinants of Neonatal Iron Homeostasis in Women Carrying Multiples

TypeobservationalSponsorCornell UniversityRan2011 to 2023Enrolled350ConditionsAnemia
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Alexa BaradDivision of Nutritional Sciences, Cornell University, Ithaca, NY, United States.
Ronnie GuilletDepartment of Pediatrics, Neonatology, University of Rochester School of Medicine, Rochester, NY, United States.
Eva K PressmanDepartment of Obstetrics and Gynecology, University of Rochester School of Medicine, Rochester, NY, United States.
Philip J KatzmanDepartment of Pathology and Clinical Laboratory Medicine, University of Rochester School of Medicine, Rochester, NY, United States.
Tomas GanzCenter for Iron Disorders, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Elizabeta NemethCenter for Iron Disorders, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Kimberly O O'BrienDivision of Nutritional Sciences, Cornell University, Ithaca, NY, United States. Electronic address: koo4@cornell.edu.
University of Rochester · USCornell University · USUniversity of California, Los Angeles · US

Funding

Iron physiology and pathology in pregnancyR01HD096863 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEMETH, ELIZABETA · 2019 to 2023
$2.1M
Erythroferrone and Its Impact on Maternal and Neonatal Iron HomeostasisR21HD098864 · NICHD · CORNELL UNIVERSITY · PI NEMETH, ELIZABETA, O'BRIEN, KIMBERLY O · 2019 to 2020
$445k
Adverse Interaction Between Iron Deficiency and Inflammation in PregnancyR21HD104014 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEMETH, ELIZABETA · 2021 to 2022
$429k
NICHD NIH HHS R01 HD096863NICHD NIH HHS R21 HD098864NICHD NIH HHS R21 HD104014
6 · The paper itself

Abstract

backgroundMurine data suggest that the placenta downregulates ferroportin (FPN) when iron is limited to prioritize iron for its own needs. Human data on the impact of maternal and neonatal iron status on placental FPN expression are conflicting.

objectivesThis study aimed to identify determinants of placental FPN protein abundance and to assess the utility of the placental iron deficiency index (PIDI) as a measure of maternal/fetal iron status in newborns at high risk for anemia.

methodsPlacental FPN protein abundance was measured by western blots in placentae collected from 133 neonates born to adolescents (17.4 ± 1.1 y) carrying singletons (delivery gestational age [GA]: 39.9 ± 1.3 wk) and from 130 neonates born to 65 females (30.4 ± 5.2 y) carrying multiples (delivery GA: 35.0 ± 2.8 wk). Placental FPN and the PIDI (FPN:transferrin receptor 1) were evaluated in relation to neonatal and maternal iron-related markers (hemoglobin [Hb], serum ferritin [SF], soluble transferrin receptor [sTfR], total body iron [TBI], hepcidin, erythropoietin [EPO], erythroferrone).

resultsFPN protein was detected in all placentae delivered between 25 and 42 wk GA. Placental FPN protein abundance was associated with neonatal iron and erythropoietic markers (EPO: β: 0.10; 95% confidence interval [CI]: 0.06, 0.35; sTfR: β: 0.20; 95% CI: 0.03, 0.18; hepcidin: β: -0.06; 95% CI: -0.13, -0.0003; all P < 0.05). Maternal sTfR was only indirectly associated with placental FPN, with neonatal sTfR as the mediator (β-indirect: 0.06; 95% CI; 0.03, 0.11; P = 0.003). The PIDI was associated with neonatal Hb (β: -0.02; 95% CI: -0.03, -0.003), EPO (β: 0.07; 95% CI: 0.01, 0.14), and sTfR (β: 0.13; 95% CI: 0.004, 0.3) and with maternal SF (β: 0.08, 95% CI: 0.02, 0.14), TBI (β: 0.02; 95% CI: 0.009, 0.04), EPO (β: -0.10; 95% CI: -0.19, -0.01), sTfR (β: -0.16: 95% CI: -0.27, -0.06), and hepcidin (β: 0.05; 95% CI: 0.002, 0.11) at delivery (all P < 0.05).

conclusionsPlacental FPN abundance was positively associated with neonatal indicators of increased erythropoietic activity and poor iron status. The PIDI was associated with maternal and neonatal iron-related markers but in opposite directions. More data are needed from a lower-risk normative group of females to assess the generalizability of findings. These trials were registered at clinicaltrials.gov as NCT01019902 and NCT01582802.

Indexed as

AnemiaAnemia, Iron-DeficiencyIron DeficienciesAdolescentAnimalsFemaleFerritinsFerroportinHemoglobinsHepcidinsHumansInfant, NewbornIronMicePlacentaPregnancyFerritinsFerroportinHemoglobinsHepcidinsIronReceptors, Transferrinerythropoietic activityhigh-risk pregnancyiron trafficking proteinsneonatal anemiaplacenta

Identifiers

PMID37890671
PMCPMC10808842
OpenAlexW4387996510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.